NASDAQ:PHIOPhio Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.05 +0.81 (+36.16 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$3.00Now: $3.05▼$6.4850-Day Range$1.76MA: $2.09▼$2.6352-Week Range$1.60Now: $3.05▼$25.30Volume58.50 million shsAverage Volume481,788 shsMarket Capitalization$13.97 millionP/E RatioN/ADividend YieldN/ABeta1.89 ProfileAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Phio Pharmaceuticals. Previous Next 2.4 Community Rank Outperform VotesPhio Pharmaceuticals has received 27 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPhio Pharmaceuticals has received 30 “underperform” votes. (Add your “underperform” vote.)Community SentimentPhio Pharmaceuticals has received 52.63% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Phio Pharmaceuticals and other stocks. Vote “Outperform” if you believe PHIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPhio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.14% of the stock of Phio Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 28.00% of the stock of Phio Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($2.93) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phio Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phio Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhio Pharmaceuticals has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHIO Previous Symbol CUSIPN/A CIKN/A Webphiopharma.com Phone508-767-3861Debt Debt-to-Equity Ratio0.03 Current Ratio7.02 Quick Ratio7.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales698.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.62 per share Price / Book1.16Profitability EPS (Most Recent Fiscal Year)($19.33) Net Income$-8,910,000.00 Net MarginsN/A Return on Equity-104.32% Return on Assets-82.10%Miscellaneous Employees9 Outstanding Shares4,580,000Market Cap$13.97 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable NASDAQ:PHIO Rates by TradingView Receive PHIO News and Ratings via Email Sign-up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions How has Phio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PHIO stock has increased by 10.1% and is now trading at $3.05. View which stocks have been most impacted by Coronavirus. When is Phio Pharmaceuticals' next earnings date? Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Phio Pharmaceuticals. How were Phio Pharmaceuticals' earnings last quarter? Phio Pharmaceuticals Corp (NASDAQ:PHIO) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($1.33) EPS for the quarter. View Phio Pharmaceuticals' earnings history. Has Phio Pharmaceuticals been receiving favorable news coverage? Media stories about PHIO stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Phio Pharmaceuticals earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutPhio Pharmaceuticals. Are investors shorting Phio Pharmaceuticals? Phio Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 60,200 shares, an increase of 554.3% from the April 30th total of 9,200 shares. Based on an average daily trading volume, of 413,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.3% of the company's shares are sold short. View Phio Pharmaceuticals' Current Options Chain. Who are some of Phio Pharmaceuticals' key competitors? Some companies that are related to Phio Pharmaceuticals include Forward Pharma A/S (FWP), Entasis Therapeutics (ETTX), CNS Pharmaceuticals (CNSP), Processa Pharmaceuticals (PCSA), Aileron Therapeutics (ALRN), Hoth Therapeutics (HOTH), Millendo Therapeutics (MLND), Zafgen (ZFGN), Adamis Pharmaceuticals (ADMP), PLx Pharma (PLXP), Tonix Pharmaceuticals (TNXP), Bellicum Pharmaceuticals (BLCM), Neos Therapeutics (NEOS), Acer Therapeutics (ACER) and Citius Pharmaceuticals (CTXR). View all competitors. What other stocks do shareholders of Phio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include General Motors (GM), General Mills (GIS), Ocugen (OCGN), Preferred Apartment Communities (APTS), BCE (BCE), Baidu (BIDU), Carnival (CCL), Delta Air Lines (DAL), DURECT (DRRX) and Eastman Chemical (EMN). Who are Phio Pharmaceuticals' key executives? Phio Pharmaceuticals' management team includes the following people: Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc, Pres & CEO (Age 44)Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 33) What is Phio Pharmaceuticals' stock symbol? Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO." Who are Phio Pharmaceuticals' major shareholders? Phio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (8.90%) and JPMorgan Chase & Co. (0.76%). Which institutional investors are buying Phio Pharmaceuticals stock? PHIO stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, and JPMorgan Chase & Co.. How do I buy shares of Phio Pharmaceuticals? Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Phio Pharmaceuticals' stock price today? One share of PHIO stock can currently be purchased for approximately $3.05. How big of a company is Phio Pharmaceuticals? Phio Pharmaceuticals has a market capitalization of $13.97 million and generates $20,000.00 in revenue each year. The company earns $-8,910,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis. Phio Pharmaceuticals employs 9 workers across the globe. What is Phio Pharmaceuticals' official website? The official website for Phio Pharmaceuticals is phiopharma.com. How can I contact Phio Pharmaceuticals? Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
